Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Looks To Build On Supportive Care Presence With Promacta And Rezonic

Executive Summary

Building on the base of its anti-emetic Zofran, GlaxoSmithKline is poised to broaden its leadership in the market for oncology supportive care with near-term offerings for thrombocytopenia and chemotherapy-induced nausea and vomiting

You may also be interested in...



GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May

FDA has been digesting both applications for a considerable amount of time.

Amgen’s European EPO Sales Unaffected By Biosimilars, Company Says

The European launch of biosimilar erythropoietin products has failed to impact European sales of Amgen's EPO products, EVP Worldwide Sales and Marketing George Morrow said during the company's third quarter earnings call Oct. 24

Amgen’s European EPO Sales Unaffected By Biosimilars, Company Says

The European launch of biosimilar erythropoietin products has failed to impact European sales of Amgen's EPO products, EVP Worldwide Sales and Marketing George Morrow said during the company's third quarter earnings call Oct. 24

UsernamePublicRestriction

Register

PS048500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel